Background: It is essential in clinical management to determine the disease activity in ulcerative colitis (UC) patients. At present, the most accurate way of evaluating the UC severity is endoscopy with biopsy. Fecal calprotectin (FCP) is a non-invasive biomarker that is frequently used for monitoring of intestinal inflammation. Aims: The purpose of our study was to assess the role of FCP as a noninvasive indicator for UC disease activity. Materials and methods: This prospective study enrolled 116 patients with UC (56 with quiescent UC and 60 with active UC) and 36 controls, referred for colonoscopy to our Center. Colonoscopy was performed in all the patients and the findings were graded according to Mayo endoscopic score (EMS) and UC endoscopic index of severity (UCEIS). FCP was analyzed in stool samples by means of point-of-care desk-top Quantum Blue® method. Results: There was no significant difference between mean FCP levels in controls and UC patients in remission (р=0.205). Mean FCP in patients with active UC was significantly higher than that in controls (p<0.001) and in patients in remission (p<0.001). FCP significantly correlated with UCEIS (r = 0.869, p<0.001) and EMS (r = 0.814, p<0.001).
Ulcerative colitis (UC) is a chronic, idiopathic, inflammatory disease characterized by recurrent episodes of diffuse inflammation of the large intestine's mucosa followed by periods of remission. In view of clinical management, it is essential to determine the disease activity. 1 In order to evaluate it in a given patient, doctors rely on a combination of clinical and endoscopic findings as well as levels of laboratory biomarkers. 2 At present, the most accurate way of evaluating the severity of UC and extent of intestinal inflammation is endoscopy with biopsy. 3 However, this technique has the drawbacks of being invasive, time-consuming, and expensive. Moreover, this examination is painful, and requires both a skilled operator and an uncomfortable preparatory regimen. 4 These limiting factors are often a burden to UC patients, and often prevent the frequent evaluation of UC activity by endoscopy. 5 On the other hand, patients' symptoms cannot reliably reflect the extent of disease and response to therapy, and their correlation with endoscopic activity is often limited. 6 Therefore, for quantifying the disease activity, a combination of clinical examination, levels of laboratory biomarkers, endoscopic and microscopic findings is used in routine clinical practice. 7 Several laboratory biomarkers have been evaluated for the purpose of monitoring endoscopic UC activity. 8 In UC, active inflammation is associated with an acute phase reaction and migration of leukocytes to the bowel lumen. As such, elevated levels of several proteins can be measured in serum and feces. Acute phase reactants (ESR, WBC, CRP) have been demonstrated to have very low sensitivity and specificity in correlation to intestinal inflammatory activity. 1, 9 Fecal markers, specifically, calprotectin may be more specific for assessing intestinal disease activity. 10 Calprotectin is a small calcium-binding protein consisting of two heavy and one light polypeptide chains. It is found in abundance in neutrophilic granulocytes, in which it accounts for 60% of the cytosolic fraction, as well as in monocytes and macrophages. 11 Fecal calprotectin (FCP) is a biomarker that is frequently used for monitoring inflammatory bowel disease (IBD) activity. 2 There are several different scoring systems for the endoscopic evaluation of ulcerative colitis (UC) severity, such as the endoscopic Mayo score (EMS), the modified Baron score, etc. However, none of these instruments have been validated for a reliable assessment. 13 The EMS (four-point scale with a maximum total score of 3) was developed in 1987 by Schroeder et al. 14 Within EMS a score of 0 is given for normal mucosa or inactive UC, while a score of 1 is given for mild disease with evidence of mild friability, reduced vascular pattern, and mucosal erythema. A score of 2 is indicative of moderate disease with friability, erosions, complete loss of vascular pattern, and significant erythema, and a score of 3 indicates ulceration and spontaneous bleeding. Partly due to its simplicity, the EMS is the most commonly used endoscopic activity index in clinical trials for evaluating treatment efficacy in terms of endoscopic improvement. There is an overlap in the features of the different levels of this index, which causes high interobserver variation. The most troublesome component of EMS is friability, as this is subjective and leads to inconsistent results. 15 This inconsistency has led to adaptation of the index to remove friability from level 1. 16 More recently, the Ulcerative Colitis Endoscopic Index of Severity (UCEIS) has been reported by Travis et al. 17 This score was developed as an index that captures 90% of the variance in the overall assessment of endoscopic severity. It is the first validated endoscopic index of severity in UC. 18 Basically, the UCEIS is calculated as the simple sum of three descriptors: vascular pattern (score 0-2), bleeding (score 0-3), and erosions and ulcers (score 0-3). 19 Possible total scores range from 0 to 8, and UC activity can be graded as normal, mild, moderate or severe.
AIM
The purpose of our study was to assess the role of FCP as a noninvasive indicator for UC disease activity. 20 As a remission we accepted EMS 0. UC patients with proctitis, left-sided colitis and extensive colitis were included in the study. Disease location was categorized using the Montréal Classification system. 21 An overview of the demographic patient characteristics at baseline is provided in Table 1 .
The inclusion criteria for this study were as follows:
(1) age 18-85 years, (2) complete colonoscopy with intubation of the cecum (intubation of terminal ileum was not mandatory), (3) biopsies (at least six biopsies from the areas of the colon and rectum affected by UC), (4) completion of a written informed consent, and (5) fecal specimens collected within 1-2 days before colonoscopy. Exclusion criteria were: (1) incomplete colonoscopy, (2) inadequate fecal sample, (3) colorectal cancer or colon polyps, (4) Crohn's disease, (5) indeterminate colitis, (6) history of colorectal surgery, (7) urinary incontinence (due to the risk of contamination of fecal samples), (8) pregnancy, (9) history of active non-steroidal anti-inflammatory drugs (NSAID) intake (2 tablets/week), (10) having infectious colitis, (11) primary immunodeficiency, and (12) underlying chronic disease at the time of the study. Endoscopies were performed by two experienced board-certified gastroenterologists who graded the findings according to EMS and UCEIS.
Ulcerative colitis endoscopic index of severity (UCEIS)
The UCEIS score is a tool based on a visual analogue scale (VAS) that provides a model accounting for UC endoscopic severity (Table 2) . We evaluated the patients by total colonoscopy, whereas in the original determination of the UCEIS score Travis and colleagues 17 used sigmoidoscopy. The worst affected part of the colon visualized by colonoscopy was identified and the ultimate score calculated by simply adding the scores from each component (Fig. 3) . FCP significantly correlated with UCEIS (r = 0.869) and EMS (r=0.814). For both items, p<0.001 was found (Fig.  4) . Moreover, UCEIS had very strong correlation with EMS (r = 0.922, p<0.001).
DISCUSSION
This study demonstrates the role of FCP as a noninvasive indicator for UC disease activity by showing an excellent correlation with endoscopic activity evaluated by UCEIS and EMS. Therefore, FCP can be used as an alternative to endoscopy and can be accepted as a direct biomarker of intestinal inflammation in UC patients. It is simple, less expensive and non-invasive compared to colonoscopy. Currently, there are sufficient data in the literature demonstrating relationship between FCP values and severity of intestinal inflammation in IBD. However, our results emphasize on the importance of FCP in evaluation of disease activity in relatively not small Bulgarian cohort of UC patients. The main goal of the modern IBD treatment is not just symptom amelioration but also mucosal healing (MH) achievement. Endoscopy with biopsies is the best way to evaluate MH. However, because of the drawbacks of this technique, the correlation of endoscopic activity in IBD with biomarkers such as FCP has been provoking interest in gastroenterologist during the last decade. Most studies described that FCP concentrations correlate well with endoscopic and histological IBD activity 23, 24 and thus with MH. Therefore, FCP is increasingly being used as an alternative to MH assessment. In our study, we did not find a statistically significant difference between FCP levels in controls and UC patients in remission, and thus confirmed the presence of MH. In a large study by Schoepefer et al., the mean FCP value in UC patients in remission was 42.0 μg/g, which is largely consistent with the results in the present study -47.10 μg/g. 25 In some patients with inactive UC, low-grade intestinal inflammation might occur, with higher than normal FCP values, but usually not exceeding 150 μg/g. 25 In line with this, in our group of patients with UC in remission, the highest FCP value was 136 μg/g. On the other hand, FCP concentrations in patients with active UC were so significantly higher than those of controls and patients in remission that we could not even detect a cut-off level between activity and remission in UC patients. The UCEIS score is a relatively new tool to evaluate disease activity in UC patients and is closely correlated with former endoscopic activity scores. 17 The original and modified Baron scores and the Mayo score have been widely used in the clinical practice and are easy to implement. However, recent studies have demonstrated that the rate of agreement is only 27% for endoscopic remission (Baron score 0) and 37% for moderate activity (Baron 2). 17, 18, 26 Inter-observer disagreement has been reported for the severity of inflammation in UC. 17 Therefore, the development of new methods for the assessment of severity is warranted. More recently, the UCEIS and the ulcerative colitis colonoscopic index of severity (UCCIS) were developed to address the issue of low inter-observer agreement for endoscopic scores. 17, 18, 26 Close correlation between UCEIS and FCP levels was indicated by study of Taghvaei et al. (r = 0.607, p = 0.001). 27 FCP levels in patients with an overall UCEIS >1 were considerably higher than in patients with normal colonoscopy findings. However, that study did not directly show the differences in FCP levels between the patients with a UCEIS of 0 or 1. Another recent investigation also indicated that FCP levels were correlated with EMS and UCEIS. 28 In the current study we found very strong correlation between UCEIS and the widely used EMS (r = 0.922, p<0.001 
CONCLUSION
FCP concentration demonstrated a very strong correlation with endoscopic activity in UC according to UCEIS and EMS. Our study shows the excellent role of FCP as a noninvasive indicator for UC disease activity in a relatively not small Bulgarian cohort.
